
Ryaltris is owned by Glenmark Pharmaceuticals Ltd, a publicly traded Indian pharmaceutical company listed on the NSE and BSE. In the United States the brand is distributed by Glenmark Pharmaceuticals Inc., USA of Elmwood Park, New Jersey. The fixed-dose nasal spray combines olopatadine and mometasone for seasonal allergic rhinitis and received initial FDA approval in 2022.
Parent Company
Founded
2022
Status
Publicly Traded
Headquarters
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Ryaltris | Glenmark Pharmaceuticals Ltd | Subsidiary |
Ryaltris emerged from Glenmark Pharmaceuticals' respiratory research program, which sought to combine two established allergy mechanisms in a single nasal spray: a fast-acting antihistamine and an anti-inflammatory corticosteroid. The chosen pairing was olopatadine hydrochloride, a histamine-1 receptor blocker, and mometasone furoate, a proven nasal corticosteroid.
Development proceeded through clinical trials in the United States, where the fixed-dose combination demonstrated relief of both nasal and ocular symptoms of seasonal allergic rhinitis, with onset within about 15 minutes in trial data. Glenmark pursued the product as a proprietary branded drug rather than a generic, making it a showcase for the company's strategy of moving up the value chain from generics into innovative formulations.
The US Food and Drug Administration granted initial approval in January 2022 for adults and children 12 years and older, making Ryaltris one of the few fixed-dose antihistamine-steroid nasal combinations on the American market. Glenmark launched it in the US through its New Jersey subsidiary, positioning it against single-ingredient sprays and the small set of competing combinations.
Label expansion followed. In July 2026 the FDA extended the indication to children aged 6 years and older, broadening the addressable patient population. Outside the US, Ryaltris reached Canada in March 2023 through Glenmark Specialty SA and has been marketed in additional countries through the group's international specialty business and regional partners.
As of November 2026, Ryaltris remains a prescription-only product sold in metered nasal spray form, with the US prescribing information updated that July to reflect the expanded pediatric indication.
Who owns Glenmark Pharmaceuticals Ltd?
It is a publicly traded company on the NSE and BSE. The founding Saldanha family retains promoter control, with chairman Glenn Saldanha leading the company alongside institutional and public shareholders.
When was Glenmark founded?
Gracias Saldanha founded it in 1977 in Mumbai, naming it after his sons Glenn and Mark. It has been led by Glenn Saldanha as chairman and managing director.
What does Glenmark make?
Generic medicines for the US and global markets, branded formulations for India, and specialty products including the Ryaltris allergic rhinitis spray, across respiratory, dermatology, oncology and other therapy areas.
How large is Glenmark financially?
Consolidated revenue for fiscal 2026 (ended March 2026) was about 169.8 billion rupees, roughly $2 billion, up approximately 27.5 percent year over year, with around 15,000 employees.
Is Glenmark a generic or branded drug company?
Both. Generics provide the revenue base in the US and India, while specialty branded products like Ryaltris and an innovative pipeline represent its higher-margin strategy.
Where does Glenmark operate?
Headquartered in Mumbai with operations in more than 80 countries, major businesses in India and the US, manufacturing in India, and subsidiaries including Glenmark Pharmaceuticals Inc., USA and Glenmark Specialty SA.
No major recalls or safety controversies specific to Ryaltris appear in US regulatory records as of November 2026. The prescribing information carries standard class warnings for nasal corticosteroids and antihistamine sprays, including local nasal effects, glaucoma and cataract risk with prolonged use, and hypersensitivity contraindications.
The brand's safety record is defined by its label rather than incident history: as a relatively recent product with a 2022 US approval, it has not accumulated the long post-market record of older rhinitis treatments. Glenmark maintains FDA-required adverse event reporting through its US subsidiary.
No direct competitors found in the same category. This could be because Ryaltrisoperates in a unique market segment or we're still building our competitor database.
Looking for brands with different ownership structures? These similar brands are not owned by Glenmark Pharmaceuticals Ltd, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by TTAM Research Institute
Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.
23andMe is privately owned, unlike Ryaltris which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
Adcock Ingram is privately owned, unlike Ryaltris which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Alfa-Pharm CJSC
Armenia's largest pharmaceutical distributor and pharmacy chain, importing medicines from more than 70 global manufacturers since 1996.
Alfa-Pharm is privately owned, unlike Ryaltris which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by All Family Pharmacy LLC
Boca Raton mail-order pharmacy at allfamilypharmacy.com known for direct-to-consumer access to ivermectin, hydroxychloroquine, and 200-plus medications.
All Family Pharmacy is privately owned, unlike Ryaltris which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Arthrex Inc.
Orthopedic device brand of privately held Arthrex Inc., specializing in arthroscopic surgery products sold in more than 100 countries.
Arthrex is privately owned, unlike Ryaltris which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Availity
The largest real-time health information network in the US, owned by a consortium of major health insurers and Novo Holdings.
Availity is privately owned, unlike Ryaltris which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.